ライフサイエンスコーパス: therapeutic target

1 Overall, these novel findings identify claudin-3 as a therapeutic target for inhibiting overactivation of Wnt-signa

2 n autoreactive CD4 T cells, highlighting its potential as a therapeutic target for treating autoimmune diseases.

3 Our results validate Plk4 as a therapeutic target in cancer patients and reveal a new role f

4 ells that highly express AR, emphasizing its potential as a therapeutic target in patients with CRPC.

5 oting function for Tet2 and suggest that Tet2 may present a therapeutic target for the treatment of non-hematologic malig

6 This interaction may represent a therapeutic target in cancers that express ephrinB1.

7 on of DN in vivo, suggesting that DGKalpha is an attractive therapeutic target for DN.

8 Our results suggest that Foxp1 might be an attractive therapeutic target for HD.

9 Sebaceous gland ACC represents an attractive therapeutic target given its central role in formation of seb

10 rs, aging, and cancer, making the TOR pathway an attractive therapeutic target.

11 edside review on preclinical validation of IDO1 as a cancer therapeutic target and on the discovery and development of a

12 logy, highlighting RRM2B as a hypoxic-specific, anti-cancer therapeutic target.

13 f a TN-alpha2beta1-JAG1-NOTCH signaling axis as a candidate therapeutic target in glioma patients.

14 Thus, TRX1 is an actionable CRPC therapeutic target through its protection against AR-induced

15 some in macrophages and indicates a potential host-directed therapeutic target to limit the damaging inflammation associa

16 Thus, Dyrk1A might be an ideal therapeutic target for Alzheimer's disease, especially for Do

17 This unconventional signaling pathway offers an innovative therapeutic target for treating hypoxic-ischemic human diseas

18 els for mechanistic biological research, disease modelling, therapeutic target identification, drug testing and regenerat

19 gulator of angiogenesis and point to its potential as a new therapeutic target for angiogenesis-related diseases.

20 establish autophagy, a downstream pathway of mTOR, as a new therapeutic target for PKD.

21 g antagonistic galanin-opioid interactions and offers a new therapeutic target for the treatment of opioid use disorder.

22 nhancing endogenous clearance of tumor cell debris is a new therapeutic target that may complement cytotoxic cancer thera

23 BRAF-V600E also represents a new therapeutic target.

24 pathophysiological role after SCI, and may provide a novel therapeutic target for SCI.

25 retaining graft-versus-leukemia effects, unveiling a novel therapeutic target in aGVHD treatment or prevention.

26 that RUNX1 has oncogenic roles and reveal RUNX1 as a novel therapeutic target in T-ALL.

27 ollectively, these data suggest that the Bim may be a novel therapeutic target in the treatment of SLE.

28 P1 complex during mitochondrial fission and provide a novel therapeutic target to control excessive fission and associate

29 Our results suggest that MCAM may serve as a novel therapeutic target to overcome chemoresistance in SCLC.

30 Our findings highlight TBX2 as a novel therapeutic target upstream of WNT3A, where WNT3A antagonists

31 Our data identified Runx1 as a novel therapeutic target with translational potential to counteract

32 7 is a potent regulator of ROS induction and may be a novel therapeutic target.

33 ocaine reinforcement, we serendipitously identified a novel therapeutic target: DAT oligomer complexes.

34 sthma-like features, highlighting HMGB1 as a possible novel therapeutic target.

35 s true, sleep may represent a key modifiable risk factor or therapeutic target in the preclinical phases of AD.

36 a critical contributor to skin inflammation and a possible therapeutic target in AD and psoriasis.

37 irway in an ADAM8-dependent manner, making ADAM8 a possible therapeutic target.

38 the leukaemic state and identify this enzyme as a potential therapeutic target for acute myeloid leukaemia.

39 ession and function in patients with EoE and is a potential therapeutic target for EoE and related eosinophilic and aller

40 moting Treg cell differentiation, thus offering a potential therapeutic target for HCC.

41 nd breast cancer metastasis and suggest PLD2 as a potential therapeutic target for metastatic breast cancer.

42 on in PDAC development and suggest that NOX4 is a potential therapeutic target for PDAC.

43 velopment and maintenance of TCL and represents a potential therapeutic target for TCL.

44 generation of cartilaginous tissue and serve as a potential therapeutic target in the treatment of OA.

45 tion after APAP overdose and identified GSK3 as a potential therapeutic target to improve liver regeneration after APAP-i

46 ignaling pathways and suggest that Gab2 might be a powerful therapeutic target for HCC.

47 indicating that Ep3 receptor activation may be a promising therapeutic target for acute MI.

48 Thus, we have identified the Nrf2 pathway as a promising therapeutic target for CKD.

49 These data suggest that Shp2 is a relevant therapeutic target in demyelinating diseases such as multiple

50 eutic intervention will be highly dependent on the specific therapeutic target and the stage of PVR.